217 related articles for article (PubMed ID: 35708914)
1. MERTK activation drives osimertinib resistance in EGFR-mutant non-small cell lung cancer.
Yan D; Huelse JM; Kireev D; Tan Z; Chen L; Goyal S; Wang X; Frye SV; Behera M; Schneider F; Ramalingam SS; Owonikoko T; Earp HS; DeRyckere D; Graham DK
J Clin Invest; 2022 Aug; 132(15):. PubMed ID: 35708914
[TBL] [Abstract][Full Text] [Related]
2. MERTK Promotes Resistance to Irreversible EGFR Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancers Expressing Wild-type
Yan D; Parker RE; Wang X; Frye SV; Earp HS; DeRyckere D; Graham DK
Clin Cancer Res; 2018 Dec; 24(24):6523-6535. PubMed ID: 30194074
[TBL] [Abstract][Full Text] [Related]
3. Thermal treatment decreases resistance to osimertinib in non-small cell lung cancer through the EGFR/PI3K/AKT pathway.
Wang J; Ling X; Zhou M; Ding G; Peng B; Wan J
Neoplasma; 2021 May; 68(3):535-545. PubMed ID: 33724860
[TBL] [Abstract][Full Text] [Related]
4. Characterization of osimertinib (AZD9291)-resistant non-small cell lung cancer NCI-H1975/OSIR cell line.
Tang ZH; Jiang XM; Guo X; Fong CM; Chen X; Lu JJ
Oncotarget; 2016 Dec; 7(49):81598-81610. PubMed ID: 27835594
[TBL] [Abstract][Full Text] [Related]
5. P21-activated kinase 2-mediated β-catenin signaling promotes cancer stemness and osimertinib resistance in EGFR-mutant non-small-cell lung cancer.
Yi Y; Li P; Huang Y; Chen D; Fan S; Wang J; Yang M; Zeng S; Deng J; Lv X; Luo K; He Z; Liu H
Oncogene; 2022 Sep; 41(37):4318-4329. PubMed ID: 35986102
[TBL] [Abstract][Full Text] [Related]
6. MUC1-C Is a Common Driver of Acquired Osimertinib Resistance in NSCLC.
Haratake N; Ozawa H; Morimoto Y; Yamashita N; Daimon T; Bhattacharya A; Wang K; Nakashoji A; Isozaki H; Shimokawa M; Kikutake C; Suyama M; Hashinokuchi A; Takada K; Takenaka T; Yoshizumi T; Mitsudomi T; Hata AN; Kufe D
J Thorac Oncol; 2024 Mar; 19(3):434-450. PubMed ID: 37924972
[TBL] [Abstract][Full Text] [Related]
7. ONO-7475, a Novel AXL Inhibitor, Suppresses the Adaptive Resistance to Initial EGFR-TKI Treatment in
Okura N; Nishioka N; Yamada T; Taniguchi H; Tanimura K; Katayama Y; Yoshimura A; Watanabe S; Kikuchi T; Shiotsu S; Kitazaki T; Nishiyama A; Iwasaku M; Kaneko Y; Uchino J; Uehara H; Horinaka M; Sakai T; Tanaka K; Kozaki R; Yano S; Takayama K
Clin Cancer Res; 2020 May; 26(9):2244-2256. PubMed ID: 31953310
[TBL] [Abstract][Full Text] [Related]
8. Nanoparticles for co-delivery of osimertinib and selumetinib to overcome osimertinib-acquired resistance in non-small cell lung cancer.
Chen W; Yu D; Sun SY; Li F
Acta Biomater; 2021 Jul; 129():258-268. PubMed ID: 34048974
[TBL] [Abstract][Full Text] [Related]
9. Osimertinib resistance in non-small cell lung cancer: Mechanisms and therapeutic strategies.
Tang ZH; Lu JJ
Cancer Lett; 2018 Apr; 420():242-246. PubMed ID: 29425688
[TBL] [Abstract][Full Text] [Related]
10. Landscape of Acquired Resistance to Osimertinib in
Piotrowska Z; Isozaki H; Lennerz JK; Gainor JF; Lennes IT; Zhu VW; Marcoux N; Banwait MK; Digumarthy SR; Su W; Yoda S; Riley AK; Nangia V; Lin JJ; Nagy RJ; Lanman RB; Dias-Santagata D; Mino-Kenudson M; Iafrate AJ; Heist RS; Shaw AT; Evans EK; Clifford C; Ou SI; Wolf B; Hata AN; Sequist LV
Cancer Discov; 2018 Dec; 8(12):1529-1539. PubMed ID: 30257958
[TBL] [Abstract][Full Text] [Related]
11. Activation of insulin-like growth factor-1 receptor confers acquired resistance to osimertinib in non-small cell lung cancer with EGFR T790M mutation.
Hayakawa D; Takahashi F; Mitsuishi Y; Tajima K; Hidayat M; Winardi W; Ihara H; Kanamori K; Matsumoto N; Asao T; Ko R; Shukuya T; Takamochi K; Hayashi T; Suehara Y; Takeda Nakamura I; Ueno T; Kohsaka S; Mano H; Takahashi K
Thorac Cancer; 2020 Jan; 11(1):140-149. PubMed ID: 31758670
[TBL] [Abstract][Full Text] [Related]
12. Increased Expression of IRE1α Associates with the Resistant Mechanism of Osimertinib (AZD9291)-resistant non-small Cell Lung Cancer HCC827/OSIR Cells.
Tang ZH; Su MX; Guo X; Jiang XM; Jia L; Chen X; Lu JJ
Anticancer Agents Med Chem; 2018; 18(4):550-555. PubMed ID: 28730963
[TBL] [Abstract][Full Text] [Related]
13. SOS2 modulates the threshold of EGFR signaling to regulate osimertinib efficacy and resistance in lung adenocarcinoma.
Theard PL; Linke AJ; Sealover NE; Daley BR; Yang J; Cox K; Kortum RL
Mol Oncol; 2024 Mar; 18(3):641-661. PubMed ID: 38073064
[TBL] [Abstract][Full Text] [Related]
14. Sialyltransferase ST3GAL4 confers osimertinib resistance and offers strategies to overcome resistance in non-small cell lung cancer.
Han R; Lin C; Lu C; Wang Y; Kang J; Hu C; Dou Y; Wu D; He T; Tang H; Zheng J; Li L; He Y
Cancer Lett; 2024 Apr; 588():216762. PubMed ID: 38408602
[TBL] [Abstract][Full Text] [Related]
15. Dihydroartemisinin overcomes the resistance to osimertinib in EGFR-mutant non-small-cell lung cancer.
Cai X; Miao J; Sun R; Wang S; Molina-Vila MA; Chaib I; Rosell R; Cao P
Pharmacol Res; 2021 Aug; 170():105701. PubMed ID: 34087353
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic-based combination therapy and liposomal codelivery overcomes osimertinib-resistant NSCLC via repolarizing tumor-associated macrophages.
Lin TT; Xiong W; Chen GH; He Y; Long L; Gao XF; Zhou JL; Lv WW; Huang YZ
Acta Pharmacol Sin; 2024 Apr; 45(4):867-878. PubMed ID: 38114644
[TBL] [Abstract][Full Text] [Related]
17. ERK inhibition effectively overcomes acquired resistance of epidermal growth factor receptor-mutant non-small cell lung cancer cells to osimertinib.
Li Y; Zang H; Qian G; Owonikoko TK; Ramalingam SR; Sun SY
Cancer; 2020 Mar; 126(6):1339-1350. PubMed ID: 31821539
[TBL] [Abstract][Full Text] [Related]
18. Audit of Molecular Mechanisms of Primary and Secondary Resistance to Various Generations of Tyrosine Kinase Inhibitors in Known Epidermal Growth Factor Receptor-Mutant Non-small Cell Lung Cancer Patients in a Tertiary Centre.
Suryavanshi M; Jaipuria J; Mattoo S; Dhandha S; Khatri M
Clin Oncol (R Coll Radiol); 2022 Nov; 34(11):e451-e462. PubMed ID: 35810049
[TBL] [Abstract][Full Text] [Related]
19. Ferritinophagy mediates adaptive resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer.
Wang H; Hu Q; Chen Y; Huang X; Feng Y; Shi Y; Li R; Yin X; Song X; Liang Y; Zhang T; Xu L; Dong G; Jiang F
Nat Commun; 2024 May; 15(1):4195. PubMed ID: 38760351
[TBL] [Abstract][Full Text] [Related]
20. Trametinib overcomes KRAS-G12V-induced osimertinib resistance in a leptomeningeal carcinomatosis model of EGFR-mutant lung cancer.
Fukuda K; Otani S; Takeuchi S; Arai S; Nanjo S; Tanimoto A; Nishiyama A; Naoki K; Yano S
Cancer Sci; 2021 Sep; 112(9):3784-3795. PubMed ID: 34145930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]